Cardinal Health 10-Q 2024-03-31
CAH · CIK 721371 · Form 10-Q · Period ended March 31, 2024 · Filed May 2, 2024
Revenue rose 8.8% to $54.9 billion. Operating margin was 0.7%, against 1.1% a year earlier. Net income was $258 million.
8 sections, 226K characters. Original on sec.gov · ·
| Measure | Quarter ended Mar 31, 2024 | Quarter ended Mar 31, 2023 | Change |
|---|---|---|---|
| Revenue | $54.9B | $50.5B | +8.8% |
| Operating income | $367M | $572M | -35.8% |
| Net income | $258M | $345M | -25.2% |
| Cash and equivalents | $3.72B | n/a | n/a |
| Operating margin* | 0.7% | 1.1% | -0.5 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
| Table of Contents |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
| ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2024
or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ________ to ________
Commission File Number: 1-11373
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
| Ohio | 31-0958666 | |||||||||||||||||||
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) | |||||||||||||||||||
| 7000 Cardinal Place | , | Dublin | , | Ohio | 43017 | |||||||||||||||
| (Address of principal executive offices) | (Zip Code) |
(614) 757-5000
(Registrant’s telephone number, including area code)
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common shares (without par value) | CAH | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☑ | Accelerated filer | ☐ | ||||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | ||||||||||||||
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ
The number of the registrant’s common shares, without par value, outstanding as of April 26, 2024, was the following: 243,566,952.
| Cardinal Health Q3 Fiscal 2024 Form 10-Q |
Table of Contents
About Cardinal Health
Cardinal Health, Inc., an Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination. Effective January 1, 2024, we began operating under an updated organizational structure and re-aligned our financial reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions ("PSS") segment and Global Medical Products and Distribution ("GMPD") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics. As used in this report, “we,” “our,” “us,” and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2024 and fiscal 2023 and to FY24 and FY23 are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.
Forward-Looking Statements
This Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “should,” “could,” “would,” “project,” “continue,” “likely,” and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our “2023 Form 10-K”), our Forms 10-Q for the quarters ending September 30, 2023 and December 31, 2023, and other SEC filings made since June 30, 2023. Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.
Non-GAAP Financial Measures
In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this Form 10-Q.
| 1 | Cardinal Health | Q3 Fiscal 2024 Form 10-Q |
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
| MD&A | Overview |
Management's Discussion and Analysis of Financial Condition and Results of Operations
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at March 31, 2024 and June 30, 2023, and in our condensed consolidated statements of earnings for the three and nine months ended March 31, 2024 and 2023. All comparisons presented are with respect to the prior-year period, unless stated otherwise. Our previously reported segment results have been recast to conform to our new reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. The discussion and analysis in this Form 10-Q should be read in conjunction with the MD&A included in our 2023 Form 10-K.
| 2 | Cardinal Health | Q3 Fiscal 2024 Form 10-Q |
| MD&A | Overview |
Overview of Consolidated Results
Revenue
During the three and nine months ended March 31, 2024, revenue increased 9 percent and 10 percent to $54.9 billion and $167.1 billion, respectively, primarily due to branded and specialty pharmaceutical sales growth from existing customers.
GAAP and Non-GAAP Operating Earnings
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||||||||||||||
| (in millions) | 2024 | 2023 | Change | 2024 | 2023 | Change | |||||||||||||||||||||||||||||
| GAAP operating earnings | $ | 367 | $ | 572 | (36) | % | $ | 835 | $ | 590 | 42 | % | |||||||||||||||||||||||
| State opioid assessment related to prior fiscal years | — | — | — | (6) | |||||||||||||||||||||||||||||||
| Shareholder cooperation agreement costs | 1 | — | 1 | 8 | |||||||||||||||||||||||||||||||
| Restructuring and employee severance | 53 | 16 | 106 | 62 | |||||||||||||||||||||||||||||||
| Amortization and other acquisition-related costs | 80 | 74 | 207 | 216 | |||||||||||||||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | 84 | 20 | 622 | 883 | |||||||||||||||||||||||||||||||
| Litigation (recoveries)/charges, net | 81 | (76) | 29 | (256) | |||||||||||||||||||||||||||||||
| Non-GAAP operating earnings | $ | 666 | $ | 606 | 10 | % | $ | 1,799 | $ | 1,497 | 20 | % |
The sum of the components and certain computations may reflect rounding adjustments.
We had GAAP operating earnings of $367 million and $572 million during the three months ended March 31, 2024 and 2023, respectively, and $835 million and $590 million during the nine months ended March 31, 2024 and 2023, respectively. GAAP operating earnings during the three and nine months ended March 31, 2024 were favorably impacted by GMPD and Pharmaceutical and Specialty Solutions segment profit. GAAP operating earnings also reflects the pre-tax non-cash goodwill impairment charges related to the GMPD segment of $90 million during the three months ended March 31, 2024 and the $671 million and $863 million during the nine months ended March 31, 2024 and 2023, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 5 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
GAAP operating earnings during the three months ended March 31, 2024 reflects $193 million of litigation charges recognized in connection with opioid-related matters, which were partially offset by a benefit of $105 million related to opioid-related prepayments. GAAP operating earnings during the three and nine months ended March 31, 2023 were favorably impacted by litigation recoveries and a reduction in litigation reserves. See "Results of Operations" section of this MD&A and Note 7 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
Non-GAAP operating earnings during the three and nine months ended March 31, 2024 increased 10 percent and 20 percent, respectively, due to increases in GMPD and Pharmaceutical and Specialty Solutions segment profit.
| 3 | Cardinal Health | Q3 Fiscal 2024 Form 10-Q |
| MD&A | Overview |
GAAP and Non-GAAP Diluted EPS
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||||||||||||||
| ($ per share) | 2024 | 2023 | Change | 2024 | 2023 | Change | |||||||||||||||||||||||||||||
| GAAP diluted EPS (1) | $ | 1.05 | $ | 1.34 | (22) | % | $ | 2.49 | $ | 1.23 | N.M. | ||||||||||||||||||||||||
| State opioid assessment related to prior fiscal years | — | — | — | 0.02 | |||||||||||||||||||||||||||||||
| Shareholder cooperation agreement costs | — | — | — | (0.02) |
Showing the first 8K of 80K characters. Open the full section
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the quantitative and qualitative market risk disclosures included in our 2023 Form 10-K since the end of fiscal 2023 through March 31, 2024.
Item 4. Controls and Procedures
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of March 31, 2024. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of March 31, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 19 | Cardinal Health | Q3 Fiscal 2024 Form 10-Q |
| Other |
Legal Proceedings
The legal proceedings described in Note 7 of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.
Item 1A. Risk Factors
Risk Factors
You should carefully consider the information in this Form 10-Q including the Risk Factors below and the risk factors discussed in "Risk Factors" and other risks discussed in our 2023 Form 10-K, our Forms 10-Q for the quarters ended December 31, 2023 and September 30, 2023, and our other filings with the SEC since June 30, 2023. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.
Changes to the U.S. healthcare environment may not be favorable to us.
Over a number of years, the U.S. healthcare industry has undergone significant changes designed to increase access to medical care, improve safety and patient outcomes, contain costs and increase efficiencies. These changes include a general decline in Medicare and Medicaid reimbursement levels, efforts by healthcare insurance companies to limit or reduce payments to pharmacies and providers, the basis for payments beginning to transition from a fee-for-service model to value-based payments and risk-sharing models and the industry shifting away from traditional healthcare venues like hospitals and into clinics, physician offices and patients’ homes.
We expect the U.S. healthcare industry to continue to change significantly in the future. Possible changes include changes in
legislation or regulations governing prescription pharmaceutical pricing, healthcare services, U.S.-based medical product manufacturing, mandated benefits, efforts to promote increased transparency in the pharmaceutical supply chain, drug shortages, further reduction of or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to further limit payments for products and services. For example, the Federal Trade Commission has issued public requests for information related to pharmaceutical wholesalers' and group purchasing organizations' impacts on generic drug shortages and the impact of pharmacy benefits managers on drug affordability and access. These possible changes, and the uncertainty surrounding these possible changes, may directly or indirectly adversely affect us.
Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
| Period | Total Number of Shares Purchased (1) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Programs (2) | Approximate Dollar Value of Shares That May Yet be Purchased Under the Program (2) (in millions) | |||||||||||||||||||
| January 2024 | 106 | $ | 105.98 | — | $ | 3,493 | |||||||||||||||||
| February 2024 | 157 | 107.33 | — | 3,493 | |||||||||||||||||||
| March 2024 | 51 | 110.14 | — | 3,493 | |||||||||||||||||||
| Total | 314 | $ | 107.33 | — | $ | 3,493 |
(1)Reflects 106, 157 and 51 common shares purchased in January, February, and March 2024, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.
(2)On June 7, 2023, our Board of Directors approved a new $3.5 billion share repurchase program, which will expire on December 31, 2027. As of March 31, 2024, we had $3.5 billion authorized for share repurchases remaining under this program.
Item 5. Other Information
Other Information
Rule 10b5-1 Plan Adoptions and Modifications
During the three months ended March 31, 2024, no director or officer adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule10b5-1 trading arrangement" as each term is defined in Section 408(a) of Regulation S-K under the Exchange Act.
| 20 | Cardinal Health | Q3 Fiscal 2024 Form 10-Q |
| Financial Statements |
Item 1. Financial Statements
Condensed Consolidated Statements of Earnings
(Unaudited)
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in millions, except per common share amounts) | 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||
| Revenue | $ | 54,911 | $ | 50,487 | $ | 167,119 | $ | 151,559 | |||||||||||||||
| Cost of products sold | 52,964 | 48,702 | 161,558 | 146,497 | |||||||||||||||||||
| Gross margin | 1,947 | 1,785 | 5,561 | 5,062 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Distribution, selling, general and administrative expenses | 1,282 | 1,179 | 3,762 | 3,567 | |||||||||||||||||||
| Restructuring and employee severance | 53 | 16 | 106 | 62 | |||||||||||||||||||
| Amortization and other acquisition-related costs | 80 | 74 | 207 | 216 | |||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | 84 | 20 | 622 | 883 | |||||||||||||||||||
| Litigation (recoveries)/charges, net | 81 | (76) | 29 | (256) | |||||||||||||||||||
| Operating earnings | 367 | 572 | 835 | 590 | |||||||||||||||||||
| Other (income)/expense, net | (7) | — | (25) | (5) | |||||||||||||||||||
| Interest expense, net | 33 | 28 | 55 | 78 | |||||||||||||||||||
| Earnings before income taxes | 341 | 544 | 805 | 517 | |||||||||||||||||||
| Provision for income taxes | 82 | 197 | 186 | 189 | |||||||||||||||||||
| Net earnings | 259 | 347 | 619 | 328 | |||||||||||||||||||
| Less: Net earnings attributable to noncontrolling interests | (1) | (2) | (3) | (3) | |||||||||||||||||||
| Net earnings attributable to Cardinal Health, Inc. | $ | 258 | $ | 345 | $ | 616 | $ | 325 | |||||||||||||||
| Earnings per common share attributable to Cardinal Health, Inc.: | |||||||||||||||||||||||
| Basic | $ | 1.06 | $ | 1.35 | $ | 2.51 | $ | 1.24 | |||||||||||||||
| Diluted | 1.05 | 1.34 | 2.49 | 1.23 | |||||||||||||||||||
| Weighted-average number of common shares outstanding: | |||||||||||||||||||||||
| Basic | 243 | 256 | 245 | 263 | |||||||||||||||||||
| Diluted | 245 | 258 | 247 | 264 | |||||||||||||||||||
| Cash dividends declared per common share | $ | 0.5006 | $ | 0.4957 | $ | 1.5018 | $ | 1.4871 |
See notes to condensed consolidated financial statements.
| 21 | Cardinal Health | Q3 Fiscal 2024 Form 10-Q |
| Financial Statements |
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||
| Net earnings | $ | 259 | $ | 347 | $ | 619 | $ | 328 | |||||||||||||||
| Other comprehensive income/(loss): | |||||||||||||||||||||||
| Foreign currency translation adjustments and other | 1 | 4 | (4) | (34) | |||||||||||||||||||
| Net unrealized gain/(loss) on derivative instruments, net of tax | (6) | — | (5) | 6 | |||||||||||||||||||
| Total other comprehensive income/(loss), net of tax | (5) | 4 | (9) | (28) | |||||||||||||||||||
| Total comprehensive income | 254 | 351 | 610 | 300 | |||||||||||||||||||
| Less: comprehensive income attributable to noncontrolling interests | (1) | (2) | (3) | (3) | |||||||||||||||||||
| Total comprehensive income attributable to Cardinal Health, Inc. | $ | 253 | $ | 349 | $ | 607 | $ | 297 |
See notes to condensed consolidated financial statements.
| 22 | Cardinal Health | Q3 Fiscal 2024 Form 10-Q |
| Financial Statements |
Condensed Consolidated Balance Sheets
| (in millions) | March 31, 2024 | June 30, 2023 | |||||||||
| (Unaudited) | |||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and equivalents | $ | 3,718 | $ | 4,043 | |||||||
| Trade receivables, net | 11,566 | 11,344 | |||||||||
| Inventories, net | 17,277 | 15,940 | |||||||||
| Prepaid expenses and other | **3, |
Showing the first 8K of 120K characters. Open the full section
Item 6. Exhibits
| Exhibits |
Exhibits
Cardinal Health Website
Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases, SEC filings and certain other information on its website.
| 42 | Cardinal Health | Q3 Fiscal 2024 Form 10-Q |
| Form 10-Q Cross Reference Index |
Form 10-Q Cross Reference Index
| Item Number | Page | |||||||
| Part I. Financial Information | ||||||||
| Item 1 | Financial Statements | 21 | ||||||
| Item 2 | Management's Discussion and Analysis of Financial Condition and Results of Operations | 2 | ||||||
| Item 3 | Quantitative and Qualitative Disclosures about Market Risk | 19 | ||||||
| Item 4 | Controls and Procedures | 19 | ||||||
| Part II. Other Information | ||||||||
| Item 1 | Legal Proceedings | 20 | ||||||
| Item 1A | Risk Factors | 20 | ||||||
| Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds | 20 | ||||||
| Item 3 | Defaults Upon Senior Securities | N/A | ||||||
| Item 4 | Mine Safety Disclosures | N/A | ||||||
| Item 5 | Other Information | 20 | ||||||
| Item 6 | Exhibits | 42 | ||||||
| Signatures | 44 |
| N/A | Not applicable |
| 43 | Cardinal Health | Q3 Fiscal 2024 Form 10-Q |
| Additional Information |
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cardinal Health, Inc. | ||||||||
| Date: | May 2, 2024 | /s/ JASON M. HOLLAR | ||||||
| Jason M. Hollar | ||||||||
| Chief Executive Officer | ||||||||
| /s/ AARON E. ALT | ||||||||
| Aaron E. Alt | ||||||||
| Chief Financial Officer |
| 44 | Cardinal Health | Q3 Fiscal 2024 Form 10-Q |